Vnitr Lek 2021, 67(6):352-356 | DOI: 10.36290/vnl.2021.092

Complete remission of necrobiotic xanthogranuloma after disappearance of monoclonal immunoglobulin induced by bortezomib, lenalidomid and dexamethasone

Zdeněk Adam1, Luděk Pour1, Zdeněk Řehák2, Klára Dvořáková3, Renata Koukalová2, Josef Feit3, Petr Kameník4, Marta Krejčí1, Martin Štork1, Martin Krejčí1, Viera Sandecká1, Ivanna Boichuk1, Zdeněk Král1
1 Interní hematologická a onkologická klinika LF MU a FN Brno
2 Oddělení nukleární medicíny Masarykův onkologický ústav Brno
3 Patologicko-anatomické oddělení, Nemocnice Jihlava
4 Interní oddělení Nemocnice Jihlava

Necrobiotic xanthogranuloma (NXG) is a rare chronic condition, belonging to the group non-Langerhans cell histiocytoses, which is relevant due to the possibility of extracutaneous involvement and association with systemic diseases, particularly monoclonal gammopathy, MGUS and multiple myeloma. The case reported here NXG was diagnosed after 1 years of evolution in patient with asymptomatic multiple myeloma. After treatment with bortezomib, lenalidomid and dexamethasone, there was evident abrupt decrease of monoclonal immunoglobulin to not measurable level (complete remission of multiple myeloma) and in the same time was evident disappearance of cutaneous and hepatic lesions of NXG on FDG-PET/CT. The etiopathogenetic association of monoclonal immunoglobulin with NXG is documented in this case report with disappearance of NXG in the time of disappearance of monoclonal immunoglobulin.

Keywords: necrobiotic xanthogranuloma, multiple myeloma, monoclonal gammopathy.

Published: October 13, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adam Z, Pour L, Řehák Z, Dvořáková K, Koukalová R, Feit J, et al.. Complete remission of necrobiotic xanthogranuloma after disappearance of monoclonal immunoglobulin induced by bortezomib, lenalidomid and dexamethasone. Vnitr Lek. 2021;67(6):352-356. doi: 10.36290/vnl.2021.092.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nelson CA, Zhong CS, Hashemi DA et al. A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. JAMA Dermatol. 2020; 156(3): 270-279. Go to original source... Go to PubMed...
    2. Král Z, Krejčí M, Kynclová J et al. Nekrobiotický xantogranulom asociovaný s monoklonální gamapatií: popis případu a přehled léčebných možností. Transfuze a hematologie dnes. 2020; 26(4): 310-319.
    3. Zahradová L, Adam Z, Fait J et al. Nekrobiotický xantogranulom - vzácná kožní komplikace u nemocného s mnohočetným myelomem. Vnitřní lékařství. 2010; 56(suppl. 2): 2S179-2S182.
    4. Sýkorová T. Histiocytózy z non-Langerhansových buněk. Klinická dermatovenerologie. první vydání. Praha: Mladá fronta. 2019. 2019: 1027-1036.
    5. Adam Z, Zahradová L,https://www.medvik.cz/bmc/refine.do?author=547627 Krejčí M. Difuzní plošná normolipemická xantomatóza a nekrobiotický xantogranulom, asociované s monoklonální gamapatií - přínos PET - CT pro stanovení rozsahu nemoci a zkušenosti s léčbou. Popis dvou případů a přehled literatury. Vnitřní lékařství. 2010; 56(11): 1158-1159. Go to PubMed...
    6. Adam Z, Veselý K, Motyčková I et al. Oční víčka se žlutými granulomy a kašel - periokulární xantogranulom dospělých spojený s astmatem. Popis případu a přehled klinických forem juvenilního xantogranulomu a terapie Vnitřní lékařství. 2012; 58(5): 365-377.
    7. Szalat R, Pirault J, Fermand JP et al. Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathy. J Intern Med. 2014; 276(3): 269-284. Go to original source... Go to PubMed...
    8. Szalat R, Arnulf B, Karlin L et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood. 2011; 118(14): 3777-3784. Go to original source... Go to PubMed...
    9. Miguel D, Lukacs J, Illing T et al. Treatment of necrobiotic xanthogranuloma - a systematic review. J Eur Acad Dermatol Venereol. 2017; 31(2): 221-235. Go to original source... Go to PubMed...
    10. : Wick MR, Patterson JW. Cutaneous paraneoplastic syndromes. Semin Diagn Pathol. 2019; 36(4): 211-228. Go to original source... Go to PubMed...
    11. Hilal T, DiCaudo DJ, Connolly SM et al. Necrobiotic xanthogranuloma: a 30-year single-center experience. Ann Hematol.2018; 97(8): 1471-1479. Go to original source... Go to PubMed...
    12. Khoschbin T, Löser C, Dippel E. Paraneoplastische Hauterkrankungen. Internist (Berl). 2019; 60(8): 775-782. Go to original source... Go to PubMed...
    13. Weidenthaler-Barth B. Klinisches und histologisches Spektrum der Palisadengranulome: Granuloma anulare, Necrobiosis lipoidica, Rheumaknoten und nekrobiotisches Xanthogranulom Hautarzt. 2017; 68(7): 541s. Go to original source... Go to PubMed...
    14. Nguyen BD. Hepatobiliary and Pancreatic: Hepatic necrobiotic xanthogranuloma. J Gastroenterol Hepatol 2017; 32(10): 1667. doi: 10.1111/jgh.13858. Go to original source... Go to PubMed...
    15. Santosaputri E, Ellis EJ, Nagiah S et al. A multisystem granulomatous disease: necrobiotic xanthogranuloma with hepatic involvement. Med J Aust. 2014; 200(8): 490-4903. Go to original source... Go to PubMed...
    16. Mello RB, Vale ECSD. Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide. An Bras Dermatol. 2019; 94(3): 337-340. Go to original source... Go to PubMed...
    17. Efebera Y, Blanchard E, Allam C et al. Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: a case report and review of the literature. Clin Lymphoma Myeloma Leuk. 2011; 11(3): 298-302. Go to original source... Go to PubMed...
    18. Mahendran P, Wee J, Chong H et al. Necrobiotic xanthogranuloma treated with lenalidomide. Clin Exp Dermatol. 2018; 43(3): 345-347. Go to original source... Go to PubMed...
    19. Dholaria BR, Cappel M, Roy V. Necrobiotic xanthogranuloma associated with monoclonal gammopathy: successful treatment with lenalidomide and dexamethasone. Ann Hematol. 2016; 95(4): 671-672. Go to original source... Go to PubMed...
    20. Ghani S, Al Ustwani O, Khalid B et al. Periorbital necrobiotic xanthogranuloma treated successfully with novel multiple myeloma therapy. Clin Adv Hematol Oncol. 2013; 11(10): 678-680. PMID.
    21. Olson RM, Harrison AR, Maltry A et al. Periorbital Necrobiotic Xanthogranuloma Successfully Treated with Intravenous Immunoglobulin. Case Rep Ophthalmol. 2018; 9(1): 70-75. Go to original source... Go to PubMed...
    22. Goyal A, O'Leary D, Vercellotti G et al. Intravenous immunoglobulin for treatment of necrobiotic xanthogranuloma. Dermatol Ther. 2019; 32(1): e12744. doi: 10.1111/dth.12744. Go to original source... Go to PubMed...
    23. Lukács J, Goetze S, Elsner P. Periocular Necrobiotic Xanthogranuloma Successfully Treated with Intravenous Immunoglobulin. Acta Derm Venereol.2017; 97(6): 754-755. Go to original source... Go to PubMed...
    24. Rubinstein A, Wolf DJ, Granstein RD. Successful treatment of necrobiotic xanthogranuloma with intravenous immunoglobulin. J Cutan Med Surg. 2013; 17(5): 347-350. Go to original source... Go to PubMed...
    25. Liszewski W, Wisniewski JD, Safah H et al. Treatment of refraktory necrobiotic xanthogranulomas with extracorporeal photopheresis and intravenous immunoglobulin. Dermatol Ther. 2014; 27(5): 268-271. Go to original source... Go to PubMed...
    26. Nambudiri VE, McLaughlin C, Lo TC et al. Successful multimodality treatment of recalcitrant necrobiotic xanthogranuloma using electron beam radiation and intravenous immunoglobulin. Clin Exp Dermatol. 2016; 41(2): 179-182. Go to original source... Go to PubMed...
    27. Pedrosa AF, Ferreira O, Calistru A et al. Necrobiotic xanthogranuloma with giant cell hepatitis, successfully treated with intravenous immunoglobulins. Dermatol Ther. 2015; 28(2): 68-70. Go to original source... Go to PubMed...
    28. Haber R, Bachour, Gemayel ME. Scleromyxedema treatment: systemic reviewand update. Intern. J Dermatol 2020; 59(10): 1191-1201. Go to original source... Go to PubMed...
    29. Eltilib M, Fenner J, Saramago I et al. Necrobiotic Xanthogranuloma on 18F-FDG PET/CT. Clin Nucl Med.2020; 45(12): 967-969. Go to original source... Go to PubMed...
    30. Hou J, Long T, Hu S. Application of F-FDG-PET/CT in necrobiotic xanthogranuloma involving multiple organs. Eur J Nucl Med Mol Imaging. 2021; 48(1): 321-322. Go to original source... Go to PubMed...
    31. Koukalová R, Selingerová I, Řehák Z et al. FDG-PET/CT v diagnostice a hodnocení léčebné odpovědi Castlemanovy choroby - retrospektivní studie 29 případů z jednoho centra. Klin. Onkol. 2021; 34(2): 1--8.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.